Xcout Intel
Ocugen, Inc.
Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis. OCU410: Another gene therapy candidate, currently being developed to address dry age-related macular degeneration (AMD). OCU200: A novel fusion protein, presently undergoing preclinical evaluation for its potential in treating diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen maintains significant strategic collaborations, including a partnership with CanSino Biologics Inc. for the joint development and manufacturing of gene therapies, and an alliance with Bharat Biotech for the commercialization of COVAXIN within the United States market. The company's corporate headquarters are situated in Malvern, Pennsylvania.
Subscribe to see Ocugen, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Ocugen, Inc. at a glance
Ocugen, Inc. is a biotech company headquartered in Malvern, United States. It is publicly listed (OCGN) with a market capitalisation of $359.5M. Xcout tracks 20 named people at Ocugen, Inc., including Rita Johnson-Greene (CFO & Principal Accounting Officer). Xcout recorded 2 job postings from Ocugen, Inc. in the last 90 days.
Ocugen, Inc. leadership
- Rita Johnson-GreeneCFO & Principal Accounting Officer
- Arun UpadhyayChief Scientific Officer and Head of Research & Development
- Mohamed GeneadChief Medical Officer
- Vijay TammaraChief Development Officer
- Durgaprasad AnnavajjulaVice President, Head of Program Management & Chief of Staff
- Shankar MusunuriCo-Founder, Chief Executive Officer & Chairman
14 more named people on record for Ocugen, Inc., with roles, board committees and tenure — see the full roster →
Hiring at Ocugen, Inc.
Xcout recorded 2 job postings from Ocugen, Inc. in the last 90 days, from a hiring record Xcout has kept since June 2026.
The weekly hiring trend, the roles and locations behind it — see Ocugen, Inc.'s hiring signals →
Ocugen, Inc. competitors
A few of Ocugen, Inc.'s closest competitors — see the full list of competitors and alternatives →
Code Biotherapeutics, Inc. is a biotechnology company headquartered in the Greater Philadelphia area. The firm focuses on next-generation gene therapies and advanced medicine.
REGENXBIO Inc. is a biotechnology company operating in the clinical stage, dedicated to developing gene therapy candidates. These therapies are designed to introduce genes into cells, aiming either to rectify genetic deficiencies or to stimulate the body's own cells to produce therapeutic proteins or antibodies to combat diseases. Central to its therapeutic development is the proprietary NAV Technology Platform, an adeno-associated virus-based gene delivery system. The company's primary investigational asset, RGX-314, is currently in Phase III clinical trials for treating wet age-related macular degeneration. Its pipeline also includes RGX-121 and RGX-111, both in Phase I/II trials for mucopolysaccharidosis type II and type I, respectively; RGX-181, which is in preclinical development for late-infantile neuronal ceroid lipofuscinosis type II disease; RGX-202, undergoing Phase I/II evaluation for Duchenne muscular dystrophy; and RGX-381, at the preclinical stage for addressing the ocular manifestations of CLN2 disease. In addition to its internal programs, REGENXBIO Inc. licenses its NAV Technology Platform to other biotech and pharmaceutical enterprises. It also maintains a collaborative and licensing agreement with Neurimmune AG for the advancement of innovative gene therapies. Founded in 2008, REGENXBIO Inc. maintains its headquarters in Rockville, Maryland.
Passage Bio, Inc. is a biopharmaceutical company dedicated to pioneering genetic therapies for conditions affecting the central nervous system. Their advanced pipeline includes PBGM01, designed to treat infantile GM1 gangliosidosis by utilizing a proprietary AAVhu68 capsid to deliver a functional GLB1 gene, which codes for the lysosomal acid beta-galactosidase enzyme, to both the brain and peripheral tissues. Another key program, PBFT02, employs an AAV1 capsid to introduce a functional granulin (GRN) gene, encoding progranulin (PGRN), to the brain as a treatment for FTD-GRN. Additionally, PBKR03 is under development for infantile Krabbe disease, leveraging a proprietary AAVhu68 capsid to deliver a functional GALC gene, responsible for producing the hydrolytic enzyme galactosylceramidase, to the brain and surrounding tissues. The company's portfolio also features PBML04 for metachromatic leukodystrophy, PBAL05 for amyotrophic lateral sclerosis, and PBCM06 for Charcot-Marie-Tooth Type 2A. Passage Bio maintains a significant research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program, alongside a development services and clinical supply agreement with Catalent Maryland, Inc. Established in 2017, the company's headquarters are located in Philadelphia, Pennsylvania.
Coave Therapeutics is a clinical-stage biotechnology company headquartered in Paris, France. The company focuses on developing life-changing gene therapies targeting rare ocular and central nervous system diseases.
GenSight Biologics is a clinical-stage biopharmaceutical company that develops gene therapies to treat neurodegenerative retinal diseases and central nervous system disorders. The company focuses on addressing conditions such as Leber Hereditary Optic Neuropathy (LHON), Retinitis Pigmentosa, and Geographic Atrophy using technologies like gene therapy, mitochondrial targeting sequences, and optogenetics.
Beacon Therapeutics is a clinical-stage biotechnology company dedicated to saving and restoring sight for people living with rare and prevalent ocular diseases. The company works to deliver advanced retinal gene therapies to patients experiencing blindness.
Get Ocugen, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Ocugen, Inc. in Xcout Intel
- 20 named people with titles, LinkedIn and board committees
- Weekly hiring history and the mix of roles behind it
- 2 corporate events with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access